1 / 12

THE INTERNATIONAL ASSOCIATION OF SAFE INJECTION TECHNOLOGY www.iasit.org 24,Chemin de Mont-Rose CH-1294 Genthod, Geneva

THE INTERNATIONAL ASSOCIATION OF SAFE INJECTION TECHNOLOGY www.iasit.org 24,Chemin de Mont-Rose CH-1294 Genthod, Geneva Switzerland. SAFE INJECTION GLOBAL NETWORK (SIGN) Annual Meeting Phnom Penh, Cambodia, 24-26 October 2002. Presented by Lillian Salerno, President. IASIT – Who Are We?.

allison
Download Presentation

THE INTERNATIONAL ASSOCIATION OF SAFE INJECTION TECHNOLOGY www.iasit.org 24,Chemin de Mont-Rose CH-1294 Genthod, Geneva

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. THE INTERNATIONAL ASSOCIATION OF SAFE INJECTION TECHNOLOGY www.iasit.org24,Chemin de Mont-RoseCH-1294 Genthod, Geneva Switzerland SAFE INJECTION GLOBAL NETWORK (SIGN)Annual MeetingPhnom Penh, Cambodia, 24-26 October 2002 Presented by Lillian Salerno, President

  2. IASIT – Who Are We? • International Association of Safe Injection Technology • Non profit Swiss-based association, registered May 2001 • Members produce approximately 90% of syringes manufactured worldwide

  3. IASIT Members • Manufacturers, developers and individuals, committed to: • promotion and proliferation of safe injection technology • prevention of syringe reuse • promotion of safe injections

  4. IASIT Membership - Three Classes • Class I - individuals or organizations currently manufacturing safe injection technology including, but not limited to, auto-disable technology • Class II - individuals or organizations developing safe injection technology including, but not limited to, auto disable technology (no sales) • Class III - individuals or organizations involved in government, public health, medical research, or education; interested in preventing reuse of syringes through the development of safe injection technology

  5. Role of IASIT • Coordinate industry as a unified group in relation to: • regulators and standard setters • international agencies which procure syringes • the public health community

  6. IASIT Participation - First Year • WHO Meeting of Interested Parties, June 2001, Geneva – attended • SIGN Meeting, August 2001, New Delhi – sponsored attendance by speaker • ISO Technical Committee Organizational Meeting, February 2002, London – attended and appointed representative to ISO Technical Committee • 12th Expert Committee Essential Drugs and Medicines, April 2002, Geneva – encouraged bundling of safe injection equipment with injectable medications • Safety Priority Project Vaccines and Biologicals, June 2002, Geneva – presented IASIT’s role

  7. IASIT Participation – First Year(continued) • XIVth International AIDS Conference, July 2002, Barcelona – sponsored booth showing safe technologies • IASIT/WHO Working Group on Curative AD Syringe Guidelines, September 2002, Ferney-Voltaire (France) – sponsored collaborative meeting • WHO Meeting of Interested Parties, October 2002, Geneva – attended • SIGN Meeting, October 2002, Phnom Penh – attend and sponsor industry dinner and international participant

  8. Syringes (All Types) • Worldwide Statistics: • Industry estimate – 30 billion units per year worldwide • 1.5 billion (5%) immunisation syringes • Unicef awarded contract for 750 million syringes • One-half of all immunisation syringes are auto-disable syringes • One half consumed in Europe, US, Canada, Japan, Australia • One half consumed in the rest of the world

  9. IASIT’s Message • Through education, IASIT strives to promote its message about new technologies: One Syringe – One Injection

  10. Manufacturers are committed to satisfy the public health community’s demand for safety and offer several designs that prevent reuse of syringes and encourage safe disposal. To achieve this we must be given: • consistent performance criteria guidelines and specifications from procurement agencies • committed syringe quantities with syringe and needle gauge sizes clearly defined • consistent and transparent quality guidelines enforced on all manufacturers

  11. Manufacturers need a consistent message from the purchasing community: • currently no worldwide standard for syringe safety or reuse prevention feature • each manufacturer has investment in either own proprietary technology or license to manufacturer a proprietary design

  12. Conclusion • As the international marketplace matures, and syringes with either auto-disable or reuse prevention features become standard for the delivery of vaccines and therapeutic injections, customers will demand the most cost-effective and clinically preferred devices. • IASIT will continue to work in cooperation with the international community to: • Ensure proper guidelines • Educate the user about the risks of reuse and the advantages of safe injection devices • Encourage all syringe manufactures to produce only safe injection devices

More Related